<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="letter"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Intensive Care</journal-id><journal-id journal-id-type="iso-abbrev">J Intensive Care</journal-id><journal-title-group><journal-title>Journal of Intensive Care</journal-title></journal-title-group><issn pub-type="epub">2052-0492</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29201378</article-id><article-id pub-id-type="pmc">5699177</article-id><article-id pub-id-type="publisher-id">264</article-id><article-id pub-id-type="doi">10.1186/s40560-017-0264-6</article-id><article-categories><subj-group subj-group-type="heading"><subject>Letter to the Editor</subject></subj-group></article-categories><title-group><article-title>Time to re-think the use of dobutamine in sepsis</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Sato</surname><given-names>Ryota</given-names></name><address><phone>+1-808-384-5007</phone><email>st051035@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Nasu</surname><given-names>Michitaka</given-names></name><address><email>m.nasu1219@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label>Department of Emergency and Critical Care Medicine, Urasoe General Hospital, Okinawa, Japan </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2188 0957</institution-id><institution-id institution-id-type="GRID">grid.410445.0</institution-id><institution>Department of Internal Medicine, John A. Burns School of Medicine, </institution><institution>University of Hawaii at Manoa, </institution></institution-wrap>1356 Lusitana Street, 7th Floor, Honolulu, HI 96813 USA </aff></contrib-group><pub-date pub-type="epub"><day>21</day><month>11</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>21</day><month>11</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>5</volume><elocation-id>65</elocation-id><history><date date-type="received"><day>23</day><month>10</month><year>2017</year></date><date date-type="accepted"><day>17</day><month>11</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Dobutamine is commonly used worldwide and included in the protocol for early goal-directed therapy (EGDT). Since the use of dobutamine in EGDT was reported, it has been considered to be an important component, especially in the treatment of septic patients with myocardial dysfunction. However, it is questionable whether dobutamine improves the mortality of sepsis and septic shock.</p><p id="Par2">In three recent randomized controlled trials (ProCESS, ProMISe, and ARISE trials), the frequency of dobutamine use was significantly higher in the EGDT group than in the standard care group, but there were no significant differences in the mortality between the groups. These results suggested that dobutamine use may have been overemphasized despite its insignificant effect on the mortality in septic patients. Further, a propensity score analysis revealed that dobutamine use was associated with higher mortality in patients with septic shock.</p><p id="Par3">Although dobutamine leads to an increase in cardiac index, myocardial oxygen demand also increases, thus increasing the risk of myocardial ischemia and tachyarrhythmia. It is well known that the mortality in sepsis complicated with atrial fibrillation (AFib) is worse than that in sepsis without AFib. A propensity score-matched analysis reported that &#x003b2;-blockers were associated with better survival in patients with sepsis complicated with AFib. Further, a randomized controlled trial reported that a short-acting &#x003b2;-blocker improved the survival in patients with septic shock. These studies also indicated the risk of &#x003b2;-stimulation during sepsis.</p><p id="Par4">Notably, improvements in surrogate markers, such as CI, do not always indicate improvements in patient-centered outcomes, such as mortality. Conversely, some evidence indicates the worsening of patient-centered outcomes despite improvements in surrogate markers.</p><p id="Par5">Thus, available evidence suggests that the benefits of dobutamine in patients with sepsis are unclear, but its use might be harmful rather than beneficial, considering the beneficial effects of &#x003b2;-blockers in sepsis that have been reported in recent clinical studies. From this perspective, we will soon have to rethink regarding dobutamine use in patients with sepsis.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Sepsis</kwd><kwd>Septic shock</kwd><kwd>Dobutamine</kwd><kwd>Inotropes</kwd><kwd>Sepsis induced cardiomyopathy</kwd><kwd>Septic cardiomyopathy</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Manuscript</title><p id="Par10">Dobutamine is a synthetic catecholamine that acts on &#x003b1;-1, &#x003b2;-1, and &#x003b2;-2 adrenergic receptors. It is commonly used worldwide and included in the protocol for early goal-directed therapy (EGDT) [<xref ref-type="bibr" rid="CR1">1</xref>]. Since the use of dobutamine in EGDT was reported, it has been considered to be an important component, especially in the treatment of septic patients with myocardial dysfunction. Currently, surviving sepsis campaign guidelines suggest the use of dobutamine in the presence of myocardial dysfunction indicated by elevated cardiac filling pressures and low cardiac output or ongoing signs of hypoperfusion, despite achieving adequate intravascular volume and mean arterial pressure [<xref ref-type="bibr" rid="CR2">2</xref>]. However, it is questionable whether dobutamine improves the mortality of sepsis and septic shock.</p><p id="Par11">The results of three randomized controlled trials (ProCESS, ProMISe, and ARISE trials) on resuscitation in sepsis have been recently published [<xref ref-type="bibr" rid="CR3">3</xref>&#x02013;<xref ref-type="bibr" rid="CR5">5</xref>]. In these trials, the frequency of dobutamine use was significantly higher in the EGDT group than in the standard care group (ProCESS trial 8.0 vs. 1.1%, respectively; <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001; ProMISe trial 8.0 vs. 1.1%, respectively; <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001; and ARISE trial 15.4 vs. 2.6%, respectively; <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001), but there were no significant differences in the mortality between the groups. Although recent meta-analysis of randomized trials suggested inodilators such as levosimendan and dobutamine might improve the survival in septic patients [<xref ref-type="bibr" rid="CR6">6</xref>], most studies comparing inotropes included in this study were small single center studies, and we have to be careful to interpret the results. Furthermore, the biggest randomized controlled trial showed no benefit of levosimendan in mortality or prevention for organ dysfunction in septic patients [<xref ref-type="bibr" rid="CR7">7</xref>]. These results suggested that use of inotropes may have been overemphasized despite its insignificant effect on the mortality in patients with sepsis. Further, a propensity score analysis revealed that dobutamine use was associated with higher mortality in patients with septic shock [<xref ref-type="bibr" rid="CR8">8</xref>].</p><p id="Par12">Conversely, in patients with low cardiac index (CI), the benefit of dobutamine use continues to be unclear. Vieillard-Baron et al. reported simultaneous Doppler echocardiographic measurement of CI and left ventricular ejection fraction (LVEF) in patients with septic shock and estimated the association between them using the following formula: CI&#x02009;=&#x02009;(0.05&#x02009;&#x000d7;&#x02009;LVEF)&#x02009;+&#x02009;0.73 [<xref ref-type="bibr" rid="CR9">9</xref>]. According to this formula, LVEF of 35% is associated with a CI of 2.5, which is the lower threshold of the normal CI range. Because maintaining supranormal CI using dobutamine is not associated with better survival [<xref ref-type="bibr" rid="CR10">10</xref>], LVEF of 35%, but not &#x0003c;&#x02009;35%, may be sufficient, and a relatively low LVEF (35&#x02013;50%) may not be associated with mortality. The population with LVEF &#x0003c;&#x02009;35% (CI&#x02009;&#x0003c;&#x02009;2.5) represents a small percentage of patients with septic shock and may be more likely to benefit from dobutamine use. However, a meta-analysis reported that dobutamine did not improve the mortality in patients with severe heart failure, both in outpatient and inpatient settings [<xref ref-type="bibr" rid="CR11">11</xref>]. In this study, mean CI ranged from 1.7 to 2.5 and mean LVEF from 20 to 35%, suggesting that dobutamine use may not be effective even in patients with low CI. Since &#x003b2;-1 receptor is known to be downregulated in patients with heart failure [<xref ref-type="bibr" rid="CR12">12</xref>], we have to be careful to interpret this result. However, even among septic patients, myocardial adrenergic responsiveness is considered to be depressed [<xref ref-type="bibr" rid="CR13">13</xref>]. Therefore, the use of dobutamine in septic patients may not be effective as well as patients with severe heart failure.</p><p id="Par13">Further, previous randomized control trials reported that maintaining higher CI than normal with dobutamine did not affect mortality while dobutamine successfully elevated CI even in patients with normal CI [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. Although dobutamine leads to an increase in CI and splanchnic blood flow [<xref ref-type="bibr" rid="CR15">15</xref>], myocardial oxygen demand also increases, thus increasing the risk of myocardial ischemia and tachyarrhythmia [<xref ref-type="bibr" rid="CR16">16</xref>]. It is well known that the mortality in sepsis complicated with atrial fibrillation (AFib) is worse than that in sepsis without AFib [<xref ref-type="bibr" rid="CR17">17</xref>]. A propensity score-matched analysis reported that &#x003b2;-blockers were associated with better survival in patients with sepsis complicated with AFib [<xref ref-type="bibr" rid="CR18">18</xref>]. Further, a randomized controlled trial reported that a short-acting &#x003b2;-blocker improved the survival in patients with septic shock [<xref ref-type="bibr" rid="CR19">19</xref>]. These studies also indicated the risk of &#x003b2;-stimulation during sepsis.</p><p id="Par14">Notably, improvements in surrogate markers, such as CI, do not always indicate improvements in patient-centered outcomes, such as mortality. Conversely, some evidence indicates the worsening of patient-centered outcomes despite improvements in surrogate markers.</p><p id="Par15">Thus, available evidence suggests that the benefits of dobutamine in patients with sepsis are unclear, but its use might be harmful rather than beneficial, considering the beneficial effects of &#x003b2;-blockers in sepsis that have been reported in recent clinical studies. From this perspective, we will soon have to rethink regarding dobutamine use in patients with sepsis.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>AFib</term><def><p id="Par6">Atrial fibrillation</p></def></def-item><def-item><term>CI</term><def><p id="Par7">Cardiac index</p></def></def-item><def-item><term>EGDT</term><def><p id="Par8">Early goal-directed therapy</p></def></def-item><def-item><term>LVEF</term><def><p id="Par9">Left ventricular ejection fraction</p></def></def-item></def-list></glossary><ack><title>Acknowledgements</title><p>Not applicable</p><sec id="FPar2"><title>Funding</title><p id="Par17">None</p></sec><sec id="FPar3"><title>Availability of data and materials</title><p id="Par18">Not applicable.</p></sec></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>RS was responsible for conception of the letter and drafted and revised the manuscript. MN helped to draft the manuscript. Both authors read and approved the final manuscript.</p></notes><notes notes-type="COI-statement"><sec id="FPar4"><title>Authors&#x02019; information</title><p id="Par19">RS is a Japanese board-certified emergency physician. MN is a Japanese board-certified emergency and critical care physician.</p></sec><sec id="FPar1"><title>Ethical approval and consent to participate</title><p id="Par16">Not applicable</p></sec><sec id="FPar5"><title>Consent for publication</title><p id="Par20">Not applicable</p></sec><sec id="FPar6"><title>Competing interests</title><p id="Par21">The authors declare that they have no competing interests.</p></sec><sec id="FPar7"><title>Publisher&#x02019;s Note</title><p id="Par22">Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rivers</surname><given-names>E</given-names></name><name><surname>Nguyen</surname><given-names>B</given-names></name><name><surname>Havstad</surname><given-names>S</given-names></name><name><surname>Ressler</surname><given-names>J</given-names></name><name><surname>Muzzin</surname><given-names>A</given-names></name><name><surname>Knoblich</surname><given-names>B</given-names></name><etal/></person-group><article-title>Early goal-directed therapy in the treatment of severe sepsis and septic shock</article-title><source>N Engl J Med</source><year>2001</year><volume>345</volume><issue>19</issue><fpage>1368</fpage><lpage>1377</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa010307</pub-id><pub-id pub-id-type="pmid">11794169</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rhodes</surname><given-names>A</given-names></name><name><surname>Evans</surname><given-names>LE</given-names></name><name><surname>Alhazzani</surname><given-names>W</given-names></name><name><surname>Levy</surname><given-names>MM</given-names></name><name><surname>Antonelli</surname><given-names>M</given-names></name><name><surname>Ferrer</surname><given-names>R</given-names></name><etal/></person-group><article-title>Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016</article-title><source>Intensive Care Med</source><year>2017</year><volume>43</volume><issue>3</issue><fpage>304</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.1007/s00134-017-4683-6</pub-id><pub-id pub-id-type="pmid">28101605</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Investigators</surname><given-names>PCESS</given-names></name><name><surname>Yealy</surname><given-names>DM</given-names></name><name><surname>Kellum</surname><given-names>JA</given-names></name><name><surname>Huang</surname><given-names>DT</given-names></name><name><surname>Barnato</surname><given-names>AE</given-names></name><name><surname>Weissfeld</surname><given-names>LA</given-names></name><etal/></person-group><article-title>A randomized trial of protocol-based care for early septic shock</article-title><source>N Engl J Med</source><year>2014</year><volume>370</volume><issue>18</issue><fpage>1683</fpage><lpage>1693</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1401602</pub-id><pub-id pub-id-type="pmid">24635773</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mouncey</surname><given-names>PR</given-names></name><name><surname>Osborn</surname><given-names>TM</given-names></name><name><surname>Power</surname><given-names>GS</given-names></name><name><surname>Harrison</surname><given-names>DA</given-names></name><name><surname>Sadique</surname><given-names>MZ</given-names></name><name><surname>Grieve</surname><given-names>RD</given-names></name><etal/></person-group><article-title>Trial of early, goal-directed resuscitation for septic shock</article-title><source>N Engl J Med</source><year>2015</year><volume>372</volume><issue>14</issue><fpage>1301</fpage><lpage>1311</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1500896</pub-id><pub-id pub-id-type="pmid">25776532</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Investigators</surname><given-names>ARISE</given-names></name><collab>ANZICS Clinical Trial Group</collab><name><surname>Peake</surname><given-names>SL</given-names></name><name><surname>Delaney</surname><given-names>A</given-names></name><name><surname>Balley</surname><given-names>M</given-names></name><name><surname>Bellomo</surname><given-names>R</given-names></name><name><surname>Cameron</surname><given-names>PA</given-names></name><etal/></person-group><article-title>Early goal-directed therapy in the treatment of severe sepsis and septic shock</article-title><source>N Engl J Med</source><year>2014</year><volume>371</volume><issue>16</issue><fpage>1496</fpage><lpage>1506</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1404380</pub-id><pub-id pub-id-type="pmid">25272316</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belletti</surname><given-names>A</given-names></name><name><surname>Benedetto</surname><given-names>U</given-names></name><name><surname>Biondi-Zoccai</surname><given-names>G</given-names></name><name><surname>Leggieri</surname><given-names>C</given-names></name><name><surname>Silvani</surname><given-names>P</given-names></name><name><surname>Angelini</surname><given-names>GD</given-names></name><etal/></person-group><article-title>The effect of vasoactive drugs on mortality in patients wuth severe sepsis and septic shock. A network meta-analysis of randomized trials</article-title><source>J Crit Care</source><year>2017</year><volume>37</volume><fpage>91</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1016/j.jcrc.2016.08.010</pub-id><pub-id pub-id-type="pmid">27660923</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gordon</surname><given-names>AC</given-names></name><name><surname>Perkins</surname><given-names>GD</given-names></name><name><surname>Singer</surname><given-names>M</given-names></name><name><surname>McAuley</surname><given-names>DF</given-names></name><name><surname>Orme</surname><given-names>RM</given-names></name><name><surname>Santhakumaran</surname><given-names>S</given-names></name><etal/></person-group><article-title>Levosimendan for the prevention of acute organ dysfunction in sepsis</article-title><source>N Engl J Med</source><year>2016</year><volume>375</volume><issue>17</issue><fpage>1638</fpage><lpage>1648</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1609409</pub-id><pub-id pub-id-type="pmid">27705084</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilkman</surname><given-names>E</given-names></name><name><surname>Kaukonen</surname><given-names>KM</given-names></name><name><surname>Pettil&#x000e4;</surname><given-names>V</given-names></name><name><surname>Kuitunen</surname><given-names>A</given-names></name><name><surname>Varpula</surname><given-names>M</given-names></name></person-group><article-title>Association between inotrope treatment and 90-day mortality in patients with septic shock</article-title><source>Acta Anaesthesiol Scand</source><year>2013</year><volume>57</volume><issue>4</issue><fpage>431</fpage><lpage>442</lpage><pub-id pub-id-type="doi">10.1111/aas.12056</pub-id><pub-id pub-id-type="pmid">23298252</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vieillard-Baron</surname><given-names>A</given-names></name><name><surname>Prin</surname><given-names>S</given-names></name><name><surname>Chergui</surname><given-names>K</given-names></name><name><surname>Dubourg</surname><given-names>O</given-names></name><name><surname>Jardin</surname><given-names>F</given-names></name></person-group><article-title>Hemodynamic instability in sepsis: bedside assessment by Doppler echocardiography</article-title><source>Am J Respir Crit Care Med</source><year>2003</year><volume>168</volume><issue>11</issue><fpage>1270</fpage><lpage>1276</lpage><pub-id pub-id-type="doi">10.1164/rccm.200306-816CC</pub-id><pub-id pub-id-type="pmid">14644922</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayes</surname><given-names>MA</given-names></name><name><surname>Timmins</surname><given-names>AC</given-names></name><name><surname>Yau</surname><given-names>EH</given-names></name><name><surname>Palazzo</surname><given-names>M</given-names></name><name><surname>Hinds</surname><given-names>CJ</given-names></name><name><surname>Watson</surname><given-names>D</given-names></name></person-group><article-title>Elevation of systemic oxygen delivery in the treatment of critically ill patients</article-title><source>N Engl J Med</source><year>1994</year><volume>330</volume><issue>24</issue><fpage>1717</fpage><lpage>1722</lpage><pub-id pub-id-type="doi">10.1056/NEJM199406163302404</pub-id><pub-id pub-id-type="pmid">7993413</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tacon</surname><given-names>CL</given-names></name><name><surname>McCaffrey</surname><given-names>J</given-names></name><name><surname>Delaney</surname><given-names>A</given-names></name></person-group><article-title>Dobutamine for patients with severe heart failure: a systematic review and meta-analysis of randomized controlled trials</article-title><source>Intensive Care Med</source><year>2012</year><volume>38</volume><issue>3</issue><fpage>359</fpage><lpage>367</lpage><pub-id pub-id-type="doi">10.1007/s00134-011-2435-6</pub-id><pub-id pub-id-type="pmid">22160239</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bristow</surname><given-names>MR</given-names></name><name><surname>Ginsburg</surname><given-names>R</given-names></name><name><surname>Minobe</surname><given-names>W</given-names></name><name><surname>Cubicciotti</surname><given-names>RS</given-names></name><name><surname>Sageman</surname><given-names>WS</given-names></name><name><surname>Lurie</surname><given-names>K</given-names></name><etal/></person-group><article-title>Decreased catecholamine sensitivity and beta-adrenergic receptor density in falling human hearts</article-title><source>N Engl J Med</source><year>1982</year><volume>307</volume><issue>4</issue><fpage>205</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.1056/NEJM198207223070401</pub-id><pub-id pub-id-type="pmid">6283349</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cariou</surname><given-names>A</given-names></name><name><surname>Pinsky</surname><given-names>MR</given-names></name><name><surname>Monchi</surname><given-names>M</given-names></name><name><surname>Laurent</surname><given-names>I</given-names></name><name><surname>Vinsonneau</surname><given-names>C</given-names></name><name><surname>Chiche</surname><given-names>JD</given-names></name><etal/></person-group><article-title>Is myocardial adrenergic responsiveness depressed in human septic shock?</article-title><source>Intensive Care Med</source><year>2008</year><volume>34</volume><issue>5</issue><fpage>917</fpage><lpage>922</lpage><pub-id pub-id-type="doi">10.1007/s00134-008-1022-y</pub-id><pub-id pub-id-type="pmid">18259725</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gattinoni</surname><given-names>L</given-names></name><name><surname>Brazzi</surname><given-names>L</given-names></name><name><surname>Pelosi</surname><given-names>P</given-names></name><name><surname>Latini</surname><given-names>R</given-names></name><name><surname>Tognoni</surname><given-names>G</given-names></name><name><surname>Pesenti</surname><given-names>A</given-names></name><etal/></person-group><article-title>A trial of goal-oriented hemodynamic therapy in critically ill patients. SvO2 Collaborative Group</article-title><source>N Engl J Med</source><year>1995</year><volume>333</volume><issue>16</issue><fpage>1025</fpage><lpage>1032</lpage><pub-id pub-id-type="doi">10.1056/NEJM199510193331601</pub-id><pub-id pub-id-type="pmid">7675044</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reyad</surname><given-names>AR</given-names></name><name><surname>Elkharboutly</surname><given-names>W</given-names></name><name><surname>Wahba</surname><given-names>A</given-names></name><name><surname>Elmorshedi</surname><given-names>M</given-names></name><name><surname>Hasaneen</surname><given-names>NA</given-names></name></person-group><article-title>Effect of intraoperative dobutamine on splanchnic tissue perfusion and outcome after Whipple surgery</article-title><source>J Crit Care</source><year>2013</year><volume>28</volume><issue>4</issue><fpage>531.e7</fpage><lpage>531.15</lpage><pub-id pub-id-type="doi">10.1016/j.jcrc.2013.02.017</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Triposkiadis</surname><given-names>F</given-names></name><name><surname>Parissis</surname><given-names>JT</given-names></name><name><surname>Starling</surname><given-names>RC</given-names></name><name><surname>Skoularigis</surname><given-names>J</given-names></name><name><surname>Louridas</surname><given-names>G</given-names></name></person-group><article-title>Current drugs and medical treatment algorithms in the management of acute decompensated heart failure</article-title><source>Expert Opin Investig Drugs</source><year>2009</year><volume>18</volume><issue>6</issue><fpage>695</fpage><lpage>707</lpage><pub-id pub-id-type="doi">10.1517/13543780902922660</pub-id><pub-id pub-id-type="pmid">19426120</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuipers</surname><given-names>S</given-names></name><name><surname>Klein Kouwenberg</surname><given-names>PM</given-names></name><name><surname>Cremer</surname><given-names>OL</given-names></name></person-group><article-title>Incidence, risk factors and outcomes of new-onset atrial fibrillation in patients with sepsis: a systematic review</article-title><source>Crit Care</source><year>2014</year><volume>18</volume><issue>6</issue><fpage>688</fpage><pub-id pub-id-type="doi">10.1186/s13054-014-0688-5</pub-id><pub-id pub-id-type="pmid">25498795</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walkey</surname><given-names>AJ</given-names></name><name><surname>Evans</surname><given-names>SR</given-names></name><name><surname>Winter</surname><given-names>MR</given-names></name><name><surname>Benjamin</surname><given-names>EJ</given-names></name></person-group><article-title>Practice patterns and outcomes of treatments for atrial fibrillation during sepsis: a propensity-matched cohort study</article-title><source>Chest</source><year>2016</year><volume>149</volume><issue>1</issue><fpage>74</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1378/chest.15-0959</pub-id><pub-id pub-id-type="pmid">26270396</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morelli</surname><given-names>A</given-names></name><name><surname>Ertmer</surname><given-names>C</given-names></name><name><surname>Westphai</surname><given-names>M</given-names></name><name><surname>Rehberg</surname><given-names>S</given-names></name><name><surname>Kampmeier</surname><given-names>T</given-names></name><name><surname>Ligges</surname><given-names>S</given-names></name><etal/></person-group><article-title>Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial</article-title><source>JAMA</source><year>2013</year><volume>310</volume><issue>16</issue><fpage>1683</fpage><lpage>1691</lpage><pub-id pub-id-type="doi">10.1001/jama.2013.278477</pub-id><pub-id pub-id-type="pmid">24108526</pub-id></element-citation></ref></ref-list></back></article>